Physician profile
Marcella Holt
NPI 1871154922
$4,041.64
in general payments reported to CMS, 2019-2025
23 companies · $820 in 2025
The $820 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $616 · 2022: $840 · 2023: $627 · 2024: $1,139 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,442 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,442.40 |
| Education | $143.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $785.43 | 2021-2025 | Farxiga |
| Calliditas Therapeutics US INC. | $337.56 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $319.72 | 2023-2025 | |
| Novo Nordisk INC | $293.55 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $281.80 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $270.71 | 2021-2025 | Ultomiris |
| Vifor Pharma, INC. | $258.21 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $232.84 | 2021-2025 | Rayaldee |
| Ardelyx, INC. | $192.23 | 2023-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $189.36 | 2021-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $179.78 | 2021-2025 | Jynarque |
| Travere Therapeutics, INC. | $124.60 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $120.35 | 2021-2022 | |
| Amgen INC. | $88.78 | 2022-2024 | Tavneos |
| Daiichi Sankyo INC. | $78.18 | 2022-2023 | Injectafer |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.62 | 2024-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $59.52 | 2024-2025 | Velphoro, Velphoro |
| Glaxosmithkline, LLC. | $46.97 | 2022-2023 | Benlysta |
| Takeda Pharmaceuticals U.S.A., INC. | $30.27 | 2022-2023 | Gattex |
| Alnylam Pharmaceuticals INC. | $22.91 | 2023 | Oxlumo |
| Scpharmaceuticals INC. | $21.72 | 2025 | |
| Ani Pharmaceuticals, INC. | $19.39 | 2024 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.14 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcella Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.